Recent studies have suggested NUMB as a possible biomarker for prognosis and/or response to certain therapies for cancer, Alzheimer’s disease, and other pathologies, with potential clinical applications [21,140,181,182,183,184]. This evidence concerns the gene NUMB and early-onset autosomal dominant Alzheimer disease.